Heat Biologics Inc (NASDAQ:PHTBX) Founder & CEO Jeffrey Wolf tells Proactive Investors the company, which is developing therapies designed to activate a patient's immune system against cancer, has dosed its first patient in its Phase 2 trial with its drug HS-110 in combination with Merck & Co's (NYSE:MRK) Keytruda to treat patients with advanced non-small cell lung cancer.
Wolf says in addition to this milestone, the North Carolina-based company will has been selected to deliver an oral presentation summarizing new data from the company's Phase 2 trial of HS-110 in combination with Bristol-Myers Squibb's (NYSE:BMY) drug Opdivo.
